Home › Sickle Cell Disease › Wisconsin › Milwaukee
Sickle Cell Disease clinical trials in Milwaukee, WI
4 studies for Sickle Cell Disease are looking for participants at sites in and around Milwaukee (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RecruitingPhase 3
- Versiti, CCBD_Milwaukee, Milwaukee
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Comprehensive Center for Bleeding Disorders, Milwaukee
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RecruitingPhase 2
- Medical College of Wisconsin, Milwaukee
A Long-term Follow-up Study in Patients Who Received BEAM-101
RecruitingObservational study
- Medical College of Wisconsin, Milwaukee
About Sickle Cell Disease
Sickle cell disease is a group of inherited disorders that affect your red blood cells. It can cause pain, anemia, and other problems. Learn about treatments.
More about Sickle Cell Disease on MedlinePlus
Sickle Cell Disease trials in other cities
- Washington, DC21 studies
- Atlanta, GA20 studies
- Memphis, TN19 studies
- Chicago, IL18 studies
- New York City, NY16 studies
- Philadelphia, PA15 studies
- Birmingham, AL14 studies
- Houston, TX12 studies
- Boston, MA12 studies
- St. Louis, MO12 studies
- Durham, NC10 studies
- Cincinnati, OH10 studies
Other studies in Milwaukee
- Cancer (all types)24 studies
- Multiple Myeloma23 studies
- Breast Cancer22 studies
- Non-Small Cell Lung Cancer21 studies
- Lung Cancer21 studies
- Non-Hodgkin Lymphoma19 studies
- Follicular Lymphoma19 studies
- Prostate Cancer19 studies
- Acute Myeloid Leukemia18 studies
- Pancreatic Cancer18 studies
- Ovarian Cancer17 studies
- Diffuse Large B-Cell Lymphoma17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.